Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Learn how bilateral extended reporting in claims-made insurance extends your ability to report claims and secures protection after policy changes or cancellations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results